Table 2 Patients' characteristics according to cancer type
From: Survival after cancer diagnosis in a cohort of HIV-positive individuals in Latin America
Non-AIDS-defining cancers (n = 219) | AIDS-defining cancers (n = 564) | Combined (n = 783) | P | |
|---|---|---|---|---|
Sex (n = 783), % (n) | < 0.001 | |||
Female | 28% (61) | 14% (79) | 18% (140) | |
Male | 72% (158) | 86% (485) | 82% (643) | |
Age at cancer diagnosis (n = 783), median (IQR) | 45 (38–54) | 37 (31–44) | 39 (32–47) | < 0.001 |
Year of cancer diagnosis (n = 783), median (IQR) | 2009 (2006–2012) | 2008 (2004–2011) | 2008 (2005–2011) | < 0.001 |
Years from HIV diagnosis to cancer diagnosis (n = 772), median (IQR) | 5.26 (2.09–11.00) | 0.82 (0.11–5.05) | 1.67 (0.18–6.74) | < 0.001 |
Years from cART initiation to cancer diagnosis (n = 749), median (IQR) | 3.08 (0.50–8.48) | 0.02 (−0.08–0.86) | 0.19 (−0.06–2.87) | < 0.001 |
Cancer diagnosis relative to cART initiation (n = 783), % (n) | < 0.001 | |||
Cancer diagnosis after cART initiation | 79% (172) | 50% (283) | 58% (455) | |
Cancer diagnosis before/at cART initiation/Did not start cART | 21% (47) | 50% (281) | 42% (328) | |
CD4 count (cells/μL) at cancer diagnosis (n = 537), median (IQR) | 376 (229–573) | 89 (29–230) | 148 (44–364) | < 0.001 |
HIV-1 RNA at cancer diagnosis (log10) (n = 422), median (IQR) | 2.6 (2.6–3.7) | 4.6 (2.6–5.2) | 3.9 (2.6–5.0) | < 0.001 |
HIV-1 RNA status (cut point = 400 copies/mL), % (n) | < 0.001 | |||
Undetectable | 70% (99) | 31% (87) | 44% (186) | |
Detectable | 30% (42) | 69% (194) | 56% (236) | |
Status (n = 783), % (n) | 0.20 | |||
Alive | 67% (147) | 72% (405) | 70% (552) | |
Dead | 33% (72) | 28% (159) | 30% (231) | |
Follow-up (yrs) (n = 783), median (IQR) | 2.17 (0.66–5.13) | 2.62 (0.69–6.34) | 2.51 (0.69–6.13) | 0.18 |